Valuation: Ocular Therapeutix, Inc.

Market Cap 1.53B 1.37B 1.26B 1.14B 2.14B 145B 2.18B 15.04B 6.04B 76.45B 5.74B 5.62B 241B P/E 2026 *
-4.67x
P/E 2027 * -4.93x
Enterprise Value 1.11B 990M 911M 825M 1.54B 105B 1.57B 10.86B 4.36B 55.22B 4.15B 4.06B 174B EV / Sales 2026 *
20.9x
EV / Sales 2027 * 12.8x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-4.65%
1 week+7.23%
Current month-9.13%
1 month-9.13%
3 months-17.71%
6 months-25.61%
Current year-42.59%
1 week 6.4
Extreme 6.4
7.54
1 month 6
Extreme 6
7.75
Current year 6
Extreme 6
13.03
1 year 6
Extreme 6
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

General Counsel

-11,984 0.0057%
2/10/26 Sell

Executive/Senior Manager

-9,990 0.0047%
2/10/26 Sell

Chief Technology Officer

-10,869 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
-4.65%+7.23%-41.03%+182.19% 1.53B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.09%+6.03%+37.83%+93.04% 426.35B
Weighted average by Cap. +1.19%+6.60%+50.85%+98.34%

Financials

2026 *2027 *
Net sales 52.84M 47.32M 43.53M 39.44M 73.72M 5.02B 75.1M 519M 208M 2.64B 198M 194M 8.32B 102M 91.39M 84.06M 76.17M 142M 9.69B 145M 1B 402M 5.1B 383M 375M 16.07B
Net income -334M -299M -275M -249M -466M -31.73B -475M -3.28B -1.32B -16.69B -1.25B -1.23B -52.64B -330M -296M -272M -247M -461M -31.37B -470M -3.25B -1.3B -16.5B -1.24B -1.21B -52.04B
Net Debt -425M -381M -350M -317M -593M -40.37B -604M -4.18B -1.68B -21.23B -1.6B -1.56B -66.96B -225M -201M -185M -168M -314M -21.34B -319M -2.21B -886M -11.23B -843M -825M -35.4B
Projected Income Statement - Annual - Ocular Therapeutix, Inc.
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
30/10/26 US$6.970 -4.65% 2,629,770
29/10/26 US$7.310 +0.27% 2,210,805
28/10/26 US$7.290 +8.48% 2,854,126
27/10/26 US$6.720 +3.86% 2,215,306
26/10/26 US$6.470 -0.46% 1,690,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ocular Therapeutix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.970USD
Average target price
25.45USD
Spread / Average Target
+265.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ocular Therapeutix, Inc.
  1. Stock Market
  2. Stocks
  3. OCUL Stock